About 592,805 results

Lower bevacizumab doses, agents with less systemic exposure may be safer options for ROP

Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...

Several pathways under investigation for dry AMD treatment

Jan 18th, 2022 - WAIKOLOA, Hawaii — Several pathways are under investigation for the treatment of dry age-related macular degeneration, according to a presentation at Retina 2022. “The big issue for us researchers is we don’t have a good animal model to test anything,” Peter K. Kaiser, MD, said. “We don’t have preclinical models that inform us if a drug is going to work or not because the animal that we use are...

Medicare cuts, ASC rates, new FDA-approved drugs: Latest for 2022

Jan 17th, 2022 - WAIKOLOA, Hawaii — Medicare payment changes, ASC payment rates and new FDA approved drugs were a few of the topics discussed in a presentation on 2022 updates for ophthalmic practices at Hawaiian Eye 2022. Paul M. Larson, MBA, MMSC, COMT, CPC, COE, CPMA, a senior consultant from Corcoran Consulting Group, said that the Medicare Physician Fee Schedule was just updated a few weeks ago. “With the ...

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Sep 9th, 2022 - The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected...

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Arthritis & Rheumatology (Hoboken, N.J.); Fraenkel L, Bathon JM et. al.

Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising c...

In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth
Peter Izmirly, Mala Masson, Michael Marmor et. al.

Nov 14th, 2022 - Background/Purpose: The preventive approach to congenital heart block with hydroxychloroquine (HCQ) [PATCH] study supported the efficacy of HCQ to reduce the recurrence rate of cardiac disease. This study considered whether the drug had any effects upon the retinal development of these children, examined 5 years later. Methods: Mothers in the PATCH study were treated with HCQ 400mg daily from 1...

Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass, Noha Abdel-Wahab, Pankti Reid et. al.

Nov 14th, 2022 - Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify effective treatments that do not interfere with cancer responses. However, there are no studies comparing the safety or effectiveness of disease modifying anti-rheumatic drugs (DMARDs) for this condition....

Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
Jacquelyn Nestor, Christian Mancini, Baijun Zhou et. al.

Nov 14th, 2022 - Background/Purpose: Hydroxychloroquine (HCQ) is the backbone of SLE therapy, due to its benefits on increasing survival and decreasing lupus flares. In 2011, ophthalmology guidelines recommended limiting HCQ dosing to ≤6.5mg/kg of ideal body weight to reduce the risk of retinopathy; in 2016 updated guidelines recommended using ≤5mg/kg of actual body weight. For many patients, these guidelines r...

TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus
Richard Moore, Gantsetseg Tumurkhuu, Daniel Wallace and Caroline Jefferies et. al.

Nov 14th, 2022 - Background/Purpose: Patients with systemic lupus erythematosus (SLE) experience photosensitivity where exposure to ultraviolet light B (UVB) drives lupus flares and systemic symptoms. Although the mechanisms linking UVB exposure to these effects are unclear, type I IFNs are known to play a role. TRIM21, an autoantigen in SLE, functions as a negative regulator on the pathways driving IFN express...

Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Ph...
Anca Askanase, Ouali Berkani, clélia Cahuzac et. al.

Nov 14th, 2022 - Background/Purpose: Sphingosine-1-phosphate (S1P) regulates lymphocyte egress from lymphoid organs. In an SLE proof-of-concept study, cenerimod—a potent, selective S1P receptor modulator—reduced lymphocyte count and disease activity (measured by a SLEDAI-2K modified to exclude leukopenia [mSLEDAI-2K]) vs placebo (PBO) (Hermann. Lupus Sci Med 2019;6:e000354). The current phase 2 study (CARE) eva...

Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus
Eline J. Arends, Mihaela Zlei, Christopher M. Tipton et. al.

Nov 14th, 2022 - Background/Purpose: Belimumab (BEL), a recombinant human monoclonal antibody directed against B-cell activating factor (BAFF), is the first approved biological agent for patients (pts) with active systemic lupus erythematosus (SLE) and lupus nephritis (LN). BEL inhibits primary humoral immune responses by depleting naïve B cells that are dependent on BAFF for their survival while secondary humo...

Safety Profile of Hydroxychloroquine in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Toni Rush, Rachel Robbins, Angelique Collamer2 and Jess Edison et. al.

Nov 14th, 2022 - Background/Purpose: Hydroxychloroquine (HCQ) is a well-established conventional synthetic DMARD for many rheumatologic conditions. While generally believed to be safe, HCQ use is associated with a wide range of adverse effects with little knowledge of their true frequency. We set out to define the incidence and estimate the risk of known adverse events utilizing a large longitudinal database. M...

Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Ken Yasaka, Tomohide Yamazaki, Hiroko Sato et. al.

Nov 14th, 2022 - Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with minimal adverse effects and dependence on corticosteroids. Some phenotypically distinct B cell populations including IgD-, CD27-, CD11c+, and CXCR5lo double negative 2 (DN2) B cells, are expanded ...

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Alfredo Aguirre, Kimberly DeQuattro, Patricia Katz et. al.

Nov 14th, 2022 - Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to one-fifth of patients with systemic lupus erythematosus (SLE), but little is known about the relationship between these concerns and relevant health outcomes. In a multiethnic cohort of patients with SLE, we ass...

Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Kathryn Connelly, Laura Eades, Rachel Koelmeyer et. al.

Nov 14th, 2022 - Background/Purpose: Most late-phase randomised controlled trials (RCTs) of novel drugs for systemic lupus erythematosus (SLE) have failed to meet their primary endpoint or shown contradictory efficacy results(1). While many factors contribute to RCT failure, how best to measure treatment benefit remains a challenge(1). For product approval, regulators require evidence of clinical benefit, defin...

Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
Astrid Rasmussen, R. Hal Scofield, Kiely Grundahl et. al.

Nov 14th, 2022 - Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in SLE and multiple sclerosis have shown that Met associates with reduced Th17 cells, IL-17, IL-1b, IL-6, IFN-g, and TNF-a, while restoring or increasing regulatory T-cells (Treg). Sjögren’s D...

Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
Jesus Diaz, Guillermo Quiceno2 and Adela Castro, Hamilton Medical Center et. al.

Nov 14th, 2022 - Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly comparing their clinical efficacy (1)(2). In such situations, network meta-analysis (NMA) can be useful. This study aims to compare the efficacy of biologics and targeted synthetic therapies for patients w...

Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Laura Pina Vegas, Emilie sbidian2 and Pascal Claudepierre, Service de Rhumatologie et. al.

Nov 14th, 2022 - Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed, a switch to another TNFi or to another therapeutic class may be considered. However, data supporting one approach over the other are lacking. Our objective was to assess the long-term persistence of seco...

Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conduct...
Dafna Gladman, Michael Starr, Roberto Ranza et. al.

Nov 14th, 2022 - Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA achievement2. In this post hoc analysis, the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) scale was used to: (a) evaluate the long-term effect of GUS in maintaining improv...

Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
Ann E Clarke, Manuel Ugarte-Gil, Megan Barber et. al.

Nov 14th, 2022 - Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity states (DAS) on health care costs. We determined the independent impact of different definitions of remission and LDA on direct and indirect costs (DC, IC) in a multicentre, multi-ethnic inception cohort. Methods:...